Neurostimulation for the Management of Medication-Resistant Epilepsy

This program will include a discussion of devices used off-label and devices not approved by the FDA for use in the US

Background

Determination of DRE

Terminology

DRE: ILAE Guidelines

Prevalence and Consequences of DRE

Risk Factors for DRE

Changing Treatment Goals With DRE

Treatment Options for DRE

Number of Candidates for Neurostimulation Therapy

Neurostimulation Devices for Epilepsy

Heart-Brain Connection: Mechanisms and Prevalence of Cardiac Changes in Epilepsy

Vagus Nerve Stimulation Therapy: Patient Characteristics

Factors to Consider When Assessing Response to Antiseizure Therapy

Vagus Nerve Stimulation Therapy: Meta-Analysis of Efficacy

Vagus Nerve Stimulation: Later Response

Vagus Nerve Stimulation Therapy: Earlier Use Study

Long-Term Effectiveness of Vagus Nerve Stimulation: 50% Responder Rates

Randomized, Open, Prospective Trial of Vagus Nerve Stimulation on HRQoL

Impact of Vagus Nerve Stimulation on SUDEP

Responsive Neurostimulation: Patient Selection

Responsive Neurostimulation: Randomized, Double-Blind, Multicenter Trial

Responsive Neurostimulation Pivotal Study: 2-Year Responder Rates

Responsive Neurostimulation Pivotal Study: Seizure-Free Periods

Comparing Stimulation Techniques

Comparison of Device Outcomes

Conclusions

Abbreviations

Abbreviations